A Plus Biotechnology Co Ltd

Total Valuation

A Plus Biotechnology Co Ltd carries a market capitalization of 2.34B, placing it among publicly traded companies globally. Its enterprise value stands at 2.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

A Plus Biotechnology Co Ltd currently has 34.13M shares outstanding.

Valuation Ratios

A Plus Biotechnology Co Ltd trades at a trailing price-to-earnings ratio of 16.25. The price-to-sales ratio is 3.29, and the price-to-book ratio stands at 2.31.

Enterprise Valuation

On an enterprise value basis, A Plus Biotechnology Co Ltd trades at an EV/EBITDA multiple of 11.53 and an EV/FCF ratio of 13.86. The EV/Sales ratio of 2.88 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.53 provides insight into valuation relative to core operating earnings.

Financial Position

A Plus Biotechnology Co Ltd maintains a current ratio of 5.99, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.60, indicating elevated leverage, while an interest coverage ratio of 96.34 demonstrates strong ability to service its debt obligations.

Financial Efficiency

A Plus Biotechnology Co Ltd posts a return on equity of 15.53 and a return on invested capital of 13.51.

Taxes

Over the trailing twelve months, A Plus Biotechnology Co Ltd has paid 46.60M in income taxes, reflecting an effective tax rate of 21.56.

Stock Price Statistics

A Plus Biotechnology Co Ltd's stock has declined approximately -30.29382% over the past 52 weeks. The 50-day moving average sits at 73.34, while the 200-day moving average is 80.54.

Income Statement

Over the trailing twelve months, A Plus Biotechnology Co Ltd generated 835.89M in revenue and converted that into 169.38M in net income, yielding earnings per share of 5.25. EBITDA reached 208.76M, while operating income came in at 208.76M.

Balance Sheet

A Plus Biotechnology Co Ltd holds 609.35M in cash and equivalents against 96.16M in total debt, resulting in a net debt position of -517.09M. Total book value stands at 1.26B, with working capital of 988.93M providing operational flexibility.

Cash Flow

A Plus Biotechnology Co Ltd produced 158.91M in operating cash flow over the past twelve months. After subtracting -13.12M in capital expenditures, free cash flow totaled 145.79M - equivalent to 4.53 per share.

Margins

A Plus Biotechnology Co Ltd operates with a gross margin of 68.60, reflecting its pricing power and cost economics. The operating margin of 24.97 and net profit margin of 20.26 provide insight into operational efficiency.

Dividends & Yields

Scores

A Plus Biotechnology Co Ltd posts an Altman Z-Score of 8.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.